→ Israel’s Teva is reportedly taking a hard look at a foreigner for its next CEO, sparking a patriotic row.
→ The FDA has approved Vertex’s Kalydeco for use in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. As a result, the Boston biotech bumped up its revenue projections for the year to $770 million.
→ Cinfa Biotech says its second trial for a biosimilar of Amgen’s Neulasta was positive, hitting primary and secondary endpoints.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription